Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections

NCT03009045 is registered in ClinicalTrials.gov with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center as lead sponsor.

NCT NCT03009045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase
Phase 2
Overall status
Completed
Start date
February 6, 2017
Completion date
August 6, 2021
Enrollment
44 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bone and joint infection